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Antigen cross-presentation enables dendritic cells (DCs) to present extracellular antigens
on major histocompatibility complex (MHC) I molecules, a process that plays an important
role in the induction of immune responses against viruses and tumors and in the induction
of peripheral tolerance. In order to allow intracellular processing for cross-presentation,
internalized antigens are targeted by distinct endocytic receptors toward speciﬁc endo-
somal compartments, where they are protected from rapid lysosomal degradation. From
these compartments, antigens are processed for loading onto MHC I molecules. Such
processing generally includes antigen transport into the cytoplasm, a process that is regu-
lated by members of the ER-associated degradation (ERAD) machinery. After proteasomal
degradation in the cytoplasm, antigen-derived peptides have been shown to be re-imported
into the same endosomal compartment by endosomal transporter associated with antigen
processing, another ER protein, which is recruited toward the endosomes after DC mat-
uration. In our review, we highlight the recent advances on the molecular mechanisms of
cross-presentation.We focus on the necessity of such antigen storage compartments and
point out important parallels to MHC I-restricted presentation of endogenous antigens.We
discuss the composition of such endosomes and the targeting of extracellular antigens into
this compartment by speciﬁc endocytic receptors. Finally, we highlight recent advances on
the recruitment of the cross-presentation machinery, like the members of the MHC I load-
ing complex and the ERAD machinery, from the ER toward these storage compartments,
a process that can be induced by antigen encounter or by activation of the dendritic cell
after contact with endotoxins.
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INTRODUCTION
Adaptive immune responses are induced when dendritic cells
(DCs) encounter antigens in the peripheral tissue. Upon antigen
recognition, the DC migrates toward the draining lymph node,
where it can activate antigen-speciﬁc T cells (Mellman and Stein-
man, 2001). Therefore, the corresponding antigen is internalized
by the DC and processed in specialized intracellular compart-
ments. The resulting antigen-derived peptides are subsequently
loaded on major histocompatibility complex (MHC) molecules.
Whereas antigen loading onto MHC II molecules can lead to the
activation of antigen-speciﬁc CD4+ T helper cells, peptide load-
ing onto MHC I can activate antigen-speciﬁc cytotoxic CD8+ T
cells.
In classical antigen presentation, intracellular antigens are
degraded by the cytosolic proteasome. The resulting peptides are
subsequently transported through the transporter associated with
antigen processing (TAP) complex into the ER, where they can be
loaded onto MHC I molecules (Purcell and Elliott, 2008). Exoge-
nous proteins are internalized into the dendritic cell by endocytosis
and end up in a lysosomal compartment, where they are degraded
by lysosomal proteases to be loaded onto MHC II molecules
(Trombetta et al., 2003). Apart from these classical presentation
pathways, a process termed cross-presentation allows the presen-
tation of extracellular antigens also on MHC I molecules (Bevan,
1976; Kurts et al., 1996).
Cross-presentation has been demonstrated to play an impor-
tant role in a variety of processes, including the induction of
an immune response against viruses that do not infect antigen-
presenting cells directly or against tumors of non-hematopoietic
origin (Huang et al., 1994; Sigal et al., 1999; den Haan and Bevan,
2001; Heath and Carbone, 2001).
The molecular mechanisms of antigen cross-presentation,
however, remain only partially understood. In this review,we high-
light someof the recent advances on these underlyingmechanisms.
We will focus on antigen targeting into specialized storage com-
partments, on the composition of these compartments and on the
recruitment of members of the MHC I loading machinery toward
these compartments.
THE IMPORTANCE OF ANTIGEN STORAGE COMPARTMENTS
FOR CROSS-PRESENTATION
During cross-presentation, antigen-derived peptides are loaded
onto MHC I molecules. Subsequently, these peptide–MHC I-
complexes are transported toward the cell membrane, where they
can be recognized by antigen-speciﬁc T cells. Whereas peptide-
loaded MHC II molecules are stable at the cell membrane for
several days (Cella et al., 1997), differing information on the
half-life of peptide-loaded MHC I molecules can be found in lit-
erature (Eberl et al., 1996; Rescigno et al., 1998; Cella et al., 1999;
Kukutsch et al., 2000). A direct comparison between the stability
www.frontiersin.org January 2012 | Volume 2 | Article 87 | 1
Kreer et al. Molecular mechanisms of cross-presentation
of loaded MHC I molecules and MHC II molecules, however,
showed that the half-life of loaded MHC I molecules is markedly
decreased compared to peptide-loaded MHC II molecules (van
Montfoort et al., 2009). This shorter half-life of peptide-loaded
MHC I molecules has important implications for antigen cross-
presentation. After antigen internalization, the cross-presenting
DC must migrate toward the draining lymph node to activate
antigen-speciﬁc T cells. Since this process is estimated to take
up to 48 h (Martin-Fontecha et al., 2003), a prolonged MHC
I-restricted presentation is required for efﬁcient T cell activa-
tion, implying that ongoing antigen processing and loading of
antigen-derived peptides onto MHC I molecules is indispensible.
To ensure continuous peptide loading, it is essential that internal-
ized antigens are not degraded instantlywithin the endo/lysosomal
compartments of the DC, since this would rapidly eliminate
putative epitopes for cross-presentation. For these reasons, pro-
longed cross-presentation depends on antigen storage in endo-
somal compartments, where they are protected from lysosomal
degradation.
Delamarre et al. (2005) demonstrated that DCs express less
lysosomal proteases compared to macrophages, resulting in a lim-
ited capacity for lysosomal degradation and a slower degradation
rate of internalized antigens in DCs. Additionally, antigen stability
in DCs is increased by active inhibition of lysosomal acidiﬁcation,
a process that prevents the activation of lysosomal proteases and
therefore increases cross-presentation (Hotta et al., 2006). Endo-
some acidiﬁcation is mediated by vacuolar ATPase (V-ATPase),
which transports protons from the cytosol into the endosome
(Nishi and Forgac, 2002). In DCs, this process is antagonized
by NOX2-mediated alkalization of the endosome. The NADPH
oxidase NOX2 is recruited by Rab27a toward endosomal mem-
branes (Savina et al., 2006), where it produces reactive oxygen
species (ROS). Since the production of such ROS within endo-
somes consumes large amounts of protons, it causes a strong
alkalization of the endosome lumen (Savina et al., 2006), which
neutralizes V-ATPase-mediated acidiﬁcation and a neutral endo-
somal pH can be maintained. As described above, such neutral pH
prevents rapid antigen degradation, resulting in enhanced cross-
presentation. NOX2-mediated alkalization has been shown to be
involved in cross-presentation of particulate antigens in phago-
somes (Savina et al., 2006) and of soluble antigens in endosomes
(Mantegazza et al., 2008).
The decreased expression of lysosomal proteases in DCs and
endosomal alkalization by NOX2 might also be responsible for
the high stability of antigens that are internalized by DCs in
form of immune complexes. Ferry Ossendorp and colleagues
have demonstrated that OVA-containing immune complexes were
cross-presented efﬁciently over a time period of several days (van
Montfoort et al., 2009). Importantly, nearly full-length OVA was
present for over 3 days in endosomal storage compartments, from
where it was steadily processed for cross-presentation.
Taken together, prolonged MHC I-restricted presentation
requires antigen deposition in specialized storage compartments,
where they are protected from extensive proteasomal or lysosomal
degradation and from where continuous processing for loading
onto MHC I molecules can take place.
ANTIGEN TARGETING INTO STORAGE COMPARTMENTS FOR
CROSS-PRESENTATION BY DISTINCT ENDOCYTIC
RECEPTORS
In many studies, efﬁcient antigen cross-presentation was shown to
be restricted to distinct subsets of DCs. In particular, the CD8α+
splenic DCs were shown to be much better in cross-presentation
under steady state conditions compared to their CD8α− coun-
terpart in mice (den Haan et al., 2000; Pooley et al., 2001;
Schnorrer et al., 2006). Accordingly, cross-presentation capacities
in mice lacking CD8α+ DCs were severely reduced (Hildner et al.,
2008) and the human counterpart of murine CD8α+ DCs was
also demonstrated to have superior cross-presentation capacities
(Bachem et al., 2010; Crozat et al., 2010; Jongbloed et al., 2010;
Poulin et al., 2010).
Cross-presentation of antigens targeted toward DEC-205, an
endocytic receptor that is predominantly expressed on CD8α+
splenic DCs was demonstrated to be much more efﬁcient than
antigens targeted toward DCIR2, which is only expressed on
CD8α− DCs (Dudziak et al., 2007). Additionally, speciﬁc target-
ing toward DEC-205 resulted in prolonged cross-presentation for
over 2 weeks (Bonifaz et al., 2004). It was postulated that these
differences in cross-presentation capacity are due to a reduced
overall expression of the cross-presentation machinery in CD8α−
DCs (Schnorrer et al., 2006; Dudziak et al., 2007). Indeed, NOX2-
mediated alkalization of phagosomes was demonstrated to be
more pronounced in CD8α+ DCs (Savina et al., 2009). More
recent studies demonstrate that also CD8α− DCs possess intrinsic
cross-presentation capacities, but that the mechanism by which
the DCs internalize the antigen is crucial for its cross-presentation
(Kamphorst et al., 2010). This was demonstrated using transgenic
mice expressing the human DEC-205 on both CD8α+ and CD8α−
DC subsets. Antigen targeting toward this receptor resulted in
similar levels of cross-presentation in both CD8α+ and CD8α−
DCs, indicating that also CD8α− DCs are potent cross-presenters
if the antigen is internalized via DEC-205 but not via DCIR2,
demonstrating an important role for the endocytic receptor itself
in cross-presentation.
In accordance to these ﬁndings, we previously demonstrated
a clear correlation between the mechanism of antigen internal-
ization and its presentation (Burgdorf et al., 2007). We could
show that antigens internalized by DCs via ﬂuid phase pinocy-
tosis or scavenger receptor-mediated endocytosis were rapidly
targeted toward lysosomal structures, where they were degraded
instantly and processed for presentation on MHC II molecules. If,
however, antigens were internalized via mannose receptor (MR)-
mediated endocytosis, they were not targeted toward lysosomes
but rather routed into a distinct endosomal subset, which main-
tained all characteristics of early endosomes for a prolonged time.
Importantly, from these endosomes, MR-internalized antigens
were processed exclusively for cross-presentation.
These observations emphasize the importance of the endocytic
receptor for cross-presentation and point out that the endocytic
receptor on the DC that makes contact to an antigen already deter-
mines its fate in terms of presentation. Additionally, targeting
antigens intended for cross-presentation into a separate pool of
endosomes might enable enhanced endosomal stability, which is
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essential for prolonged cross-presentation, without affecting over-
all lysosomal activity, which is essential for simultaneous MHC
II-restricted presentation.
Interestingly, the MR has also been proposed to directly
inhibit lysosomal maturation (Shimada et al., 2006; Sweet et al.,
2010), because phagosomes containing MR-internalized gly-
copeptidolipids displayed impaired phagosome–lysosome fusion.
Such alterations were only observed if the glycopeptidolipids
were endocytosed by the MR, which then was present in the
glycopeptidolipid-containing phagosomes. In both publications,
it was postulated that these effects might be due to MR-dependent
signaling inside the DC, resulting in an overall impairment of
phagosome–lysosome fusion. Another possibility would be that,
similar to the observations on the role of the MR in cross-
presentation, the MR targets the glycopeptidolipids into a separate
endosomal compartment,which does not undergo normal lysoso-
mal maturation. Further studies will reveal whether signaling via
the MR additionally alters endosomal trafﬁcking within DCs.
As described above, the different cross-presentation capacities
of CD8α+ and CD8α− splenic DCs might to a large extend be
due to the expression of different endocytic receptors. This notion
might also explain observations demonstrating that certain yeast
antigens and antigens targeted to the neonatal Fc receptor are
cross-presented to a higher extend by the CD8α− subset (Backer
et al., 2008; Baker et al., 2011). Future experiments will show
whether CD8α− DCs bear speciﬁc receptors for these antigens,
enabling their cross-presentation.
The importance of distinct endocytic receptors for cross-
presentation is further supported by experiments of the group of
Peter Cresswell. They demonstrated that expression of Fc recep-
tors, whose engagement has been shown to lead to potent cross-
presentation (van Montfoort et al., 2009), in the human 293 T
embryonic kidney cell line enables this cell line to cross-present
extracellular antigens (Giodini et al., 2009), pointing out the pos-
sibility that nearly every cell possesses intrinsic cross-presentation
capacities if the cell expresses a suited receptor.
Although the decisive role of the endocytic receptor for cross-
presentation is indubitable, this might only be one half of the
story. Increasing evidence points out that also the nature of inter-
action between the endocytic receptor and the antigen has an
important impact on antigen routing and presentation. First, it
has been demonstrated that receptor cross-linking by multiva-
lent antigens alters antigen targeting within the DC. It has been
shown that dectin-1, an endocytic receptor associated with cross-
presentation (Weck et al., 2008), targets monovalent β-glucans
into non-lysosomal compartments. If, however, dectin-1 is cross-
linked by the multivalent β-glucan zymosan, these antigens are
targeted toward lysosomal structures (Herre et al., 2004), demon-
strating that antigen valence can regulate antigen trafﬁcking and
degradation. Second, it has been shown that the regionof the endo-
cytic receptor that recognizes the antigen is of crucial importance.
Antigen targeting using antibodies speciﬁc for the carbohydrate
recognition domain of DC-SIGN has been shown to efﬁciently
deliver such antigens to lysosomal compartments for MHC II pre-
sentation (Tacken et al., 2005). A recent study by the same group
demonstrated however, that antigen targeting toward the neck
region of DC-SIGN results in prolonged antigen retention in early
endosomal compartments and in reduced lysosomal trafﬁcking
(Tacken et al., 2011). Importantly, these antigens were efﬁciently
cross-presented, demonstrating that different regions of a single
endocytic receptor can target antigens to different processing and
presentation pathways.
These ﬁndings might also provide an explanation for the
observation that antigen targeting toward the MR, which tar-
gets OVA speciﬁcally toward cross-presentation (Burgdorf et al.,
2007) as described above, can induce antigen-speciﬁc CD4+ T
cell responses (Dasgupta et al., 2007; He et al., 2007; McKenzie
et al., 2007). In these studies, antigens were targeted toward the
MR by conjugation to a MR-speciﬁc antibody, which might alter
MR-mediated antigen targeting by receptor cross-linking. Alter-
natively, these antibodies might target other regions of the MR,
resulting in different antigen processing and presentation.
In summary, efﬁcient cross-presentation requires antigen
recognition by distinct regions of speciﬁc endocytic receptors,
which target the internalized antigens toward antigen storage com-
partments, from where they can be processed for loading onto
MHC I molecules.
MOLECULAR MECHANISMS OF CROSS-PRESENTATION
THE VACUOLAR VERSUS THE PHAGOSOME-TO-CYTOSOL PATHWAY
Despite intensive investigations, the molecular mechanisms gov-
erning antigen processing and loading onto MHC I molecules
for cross-presentation are not fully resolved yet. Importantly, the
diversity of experimental evidence obtained by different research
groups indicates that multiple pathways can lead to MHC I-
restricted presentation of exogenous antigens, depending on the
nature of the antigen, the nature of the antigen-presenting cell,
and the immunological context of the cross-presentation process
(Figure 1).
In general, two major pathways are considered to be most rele-
vant for antigen cross-presentation: the vacuolar pathway and the
phagosome-to-cytosol pathway (Rock and Shen, 2005).
In the vacuolar pathway,which is also termedTAP-independent
cross-presentation, internalized antigens are degraded in endoso-
mal compartments by intra-endosomal proteases such as cathep-
sin S (Shen et al., 2004). After such degradation, antigenic peptides
are loaded within the endosomes onto MHC I molecules, which
reach the endosomes from the cell surface during endocytosis.
The acid environment in these endosomes might allow already
bound peptides to dissociate from the MHC I molecules, enabling
the peptides generated within the endosomes to bind MHC I
molecules.
Although several studies reported of cross-presentation via the
vacuolar pathway (Shen et al., 2004; Bertholet et al., 2006), its phys-
iological signiﬁcance remains unclear. Therefore, the phagosome-
to-cytosol pathway is considered to be the most relevant cross-
presentation pathway in vivo (Rock and Shen, 2005).
In the phagosome-to-cytosol pathway, internalized antigens
need to be transported from the endosomal lumen into the cyto-
plasm. Such antigen transport is required for consecutive degra-
dation by the cytosolic proteasome, which is essential for cross-
presentation by the phagosome-to-cytosol pathway (Kovacsovics-
Bankowski andRock,1995;Ackerman et al., 2003; Palmowski et al.,
2006).
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FIGURE 1 | Overview of the molecular mechanisms of
cross-presentation. In the vacuolar cross-presentation pathway,
extracellular antigens are internalized and degraded in endosomal
compartments by Cathepsin S. The resulting peptides are subsequently
loaded onto MHC I molecules within the endosomal compartment. In the
phagosome-to-cytosol pathway, internalized antigens are transported out of
the endosomes into the cytosol for proteasomal degradation. The resulting
peptides can be re-imported into the same endosomal compartment by
endosomal TAP to be loaded onto MHC I molecules there. The transport of
the cross-presentation machinery toward antigen-containing endosomes is
induced after stimulation of TLRs. Alternatively, DCs can obtain peptides
from neighboring cells via gap junctions. These peptides are thought to
subsequently enter the endogenous MHC I-restricted presentation pathway
in the ER.
ANTIGEN TRANSPORT FROM ENDOSOMAL COMPARTMENTS INTO THE
CYTOSOL AND PROTEASOMAL DEGRADATION
One of the most intriguing questions concerning the molecular
mechanisms of antigen cross-presentation is without any doubt
how antigens pass the endosomal membrane to reach the cytosol.
Although it has been demonstrated that phagosomes contain-
ing Cryptococcus neoformans lose membrane integrity (Tucker
and Casadevall, 2002) and the presence of sphingosine within the
phagosome might inﬂuence membrane stability and permeabil-
ity (Werneburg et al., 2002), it is assumed that antigen transport
into the cytoplasm is not due to disruption of the endosomal
membrane. Increasing evidence points out that a pore com-
plex spanning the endosomal membrane might rather mediate
this process. Antigen translocation has been demonstrated to be
size-selective. Although dextranes of 500 kDa and even 2,000 kDa
can still be translocated into the cytosol, the efﬁciency is clearly
lower than the transport of 40 kDa-sized dextranes (Rodriguez
et al., 1999), which supports the notion that such antigen trans-
port is not simply due to a simple disrupture of the endosomal
membrane.
Increasing evidence points out that the ER-associated degrada-
tion (ERAD) machinery plays a very central role in this antigen
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transport into the cytoplasm (Imai et al., 2005; Ackerman et al.,
2006; Giodini and Cresswell, 2008). The ERAD machinery has
been studied extensively in the context of protein dislocation
at the ER membrane. During dislocation, the ERAD machinery
mediates the transport of misfolded proteins from the ER into
the cytoplasm for proteasomal degradation, depicting an impor-
tant function in preventing misfolded proteins from reaching the
cell surface. One important member of the ERAD machinery in
respect to cross-presentation is Sec61, which is thought to build
the pore complex for dislocation of proteins trough the ER mem-
brane. Similar to its role in dislocation, Sec61 has been postulated
to build the pore complex through the endosomal membrane for
cross-presentation (Ackerman et al., 2006). This hypothesis was
based on observations, revealing that DC treatment with exo-
toxin A, which is assumed to be a speciﬁc inhibitor of Sec61,
prevented antigen translocation into the cytoplasm and hence
cross-presentation (Koopmann et al., 2000). Since such evidence
for an involvement of Sec61 in antigen translocation was based on
the effect of an inhibitor and therefore indirect, the role of Sec61
in cross-presentation has been questioned (Lin et al., 2008; Segura
andVilladangos, 2011). In these studies, it was argued that the size
of Sec61, which has been estimated to be about 5–8 Å (Van den
Berg et al., 2004),might not be sufﬁcient for antigen translocation.
However, this size was calculated for closed or empty Sec61 and it
has been postulated that the Sec61 pore complex during protein
transport might encompass up to 40–60 Å (Hamman et al., 1997).
Additionally, it has been demonstrated that proteins are unfolded
during antigen translocation into the cytosol (Giodini and Cress-
well, 2008), which might also enable them to transit also through
a narrow pore complex.
More direct evidence for an involvement of Sec61 in anti-
gen translocation was provided by experiments, in which Sec61
expression was down-regulated by siRNA (Imai et al., 2005). Such
down-regulation prevented cytosolic translocation of the antigen
and hence its degradation by the cytosolic proteasome, further
supporting an important role of Sec61. However, since Sec61 also
interferes with dislocation of MHC I molecules (Wiertz et al.,
1996), it cannot be fully excluded that reduced cross-presentation
observed in this study was due to an altered expression of MHC I
molecules. Therefore, the exact role of Sec61 in antigen transloca-
tion for cross-presentation could not be unequivocally determined
yet. Additionally, other members of the ERAD machinery, like
derlin-1, have also been proposed as candidates to build the
pore complex for antigen translocation across the endosomal
membrane during cross-presentation (Lilley and Ploegh, 2004;
Ye et al., 2004). But as for Sec61, future experiments are needed
to reveal a decisive role of these proteins in intracellular antigen
transport.
Another member of the ERAD machinery, which has been
shown to play an important role in cross-presentation, is the
soluble AAA ATPase p97 (Ackerman et al., 2006). P97, which
is associated with both Sec61 and derlin-1, is recruited toward
the endosomal membrane, where its ATPase activity provides the
energy for antigen translocation. Expression of a dominant neg-
ative mutant of p97 has been demonstrated to abolish antigen
translocation into the cytoplasm and hence cross-presentation
(Ackerman et al., 2006; Zehner et al., 2011).
Recent evidence indicates that also Igtp, a protein involved
in the generation of lipid bodies, inﬂuences antigen cross-
presentation (Bougneres et al., 2009). Since Igtp deﬁciency abol-
ishes cross-presentation but not MHC I-restricted presentation
of antigens that were introduced directly into the cytoplasm, Igtp
has been postulated as a putative regulator of antigen transport
into the cytoplasm (Desjardins, 2009). Whether Igtp and/or lipid
bodies indeed play a role in intracellular antigen translocation,
however, remains to be elucidated.
After antigen translocation into the cytoplasm, it becomes
ubiquitinated and processed by the cytoplasmic proteasome
(Kovacsovics-Bankowski and Rock, 1995; Ackerman et al., 2003;
Palmowski et al., 2006; Burgdorf et al., 2007, 2008). Importantly,
the proteasome constitution in DCs differs from most other cell
types. Within DCs, the standard catalytic subunits β1, β2, and β5
are replaced by β1i/LMP2, β2i/MECL-1, and β5i/LMP7 to build
the immunoproteasome (Macagno et al., 1999). Such immuno-
proteasomes display an altered protease activity and cleavage site
preference, resulting in the more efﬁcient generation of MHC I
epitopes (Kloetzel and Ossendorp, 2004) and the more efﬁcient
degradation of poly-ubiquitinated proteins (Seifert et al., 2010).
Recent studies additionally reported of proteasomes intermedi-
ate between constitutive proteasomes and immunoproteasomes,
in which only one or two catalytic subunits were replaced and
which displayed an additional cleavage speciﬁcity (Guillaume
et al., 2010), even enlarging the repertoire of antigens presented on
MHC I molecules. The constitutive expression of such immuno-
proteasomes provides DCs with a unique capacity to generate a
broad spectrum of peptides for loading on MHC I molecules.
Since antigens intended for cross-presentation generally enter
the DC as proteasome substrates (Norbury et al., 2004), the half-
life of the antigen is of crucial importance and epitopes that are
degraded shortly after their synthesis are cross-presented very
poorly (Wolkers et al., 2004).
LOADING OF ANTIGEN-DERIVED PEPTIDES ON MHC I MOLECULES
Subsequent to proteasomal degradation, cross-presentation
requires functional TAP activity (Kovacsovics-Bankowski and
Rock, 1995; Huang et al., 1996; Song and Harding, 1996; Norbury
et al., 1997; Ackerman et al., 2003, 2006), which led to the hypoth-
esis that proteasome-derived peptides might enter the classical
MHC I loading pathway in the ER (Kovacsovics-Bankowski and
Rock, 1995). Although direct evidence supporting this hypoth-
esis is missing, it was broadly accepted for years. First evidence
that peptide loading for cross-presentation might occur in cellular
compartments distinct from the ER was based on the observa-
tion that antigen-containing phagosomes contain members of the
MHC I loading machinery such as calreticulin, ERp57, tapasin,
β2-microglobulin, Sec61, MHC I itself, and functional TAP (Ack-
erman et al., 2003; Guermonprez et al., 2003; Houde et al., 2003).
These observations lead to the assumption that proteasome-
derived peptides might be re-imported into the same phagosomal
compartment for loading onto MHC I molecules there. Indeed,
after TAP-mediated peptide transport into these phagosomes,
the generation of peptide-loaded MHC I molecules within these
phagosomes could be detected (Guermonprez et al., 2003). Such
intra-phagosomal peptide loading was further accomplished by
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the recruitment of proteasomes toward the phagosomal mem-
brane (Houde et al., 2003), providing a spatial proximity of all
components of the cross-presentation machinery, which might be
essential to minimize rapid degradation of proteasome-derived
peptides with very limited half-life (Reits et al., 2003) by cytosolic
peptidases.
Formal evidence that peptide loading for cross-presentation
indeed takes places in antigen-containing endosomes came from
experiments that were aimed at inhibiting TAP activity in an
endosome-speciﬁc fashion (Burgdorf et al., 2008). In this study,
the soluble TAP inhibitor US6 (Ackerman et al., 2003), which
inhibits TAP activity from its luminal side,was covalently linked to
transferrin, resulting in its speciﬁc targeting to antigen-containing
endosomes. Such endosome-speciﬁc targeting abolished TAP
activity in endosomes without affecting TAP activity in the ER.
By this approach, it was demonstrated that endosomal TAP was
absolutely required for cross-presentation and that peptide load-
ing for cross-presentation of MR-internalized antigens does not
take place in the ER but occurs in antigen-containing endosomes.
Such a spatial separation of endogenous MHC I-restricted antigen
presentation and cross-presentation further supports the notion
of a strong compartmentalization of MHC I-restricted antigen
presentation (Lev et al., 2010), although peptide loading in the ER
under certain circumstances cannot be excluded.
After proteasomal degradation and TAP-mediated transport
into endosomal compartments, antigen-derived peptides must be
trimmed into the suitable size for optimal binding to MHC I mol-
ecules, a function that is exerted in the endogenous MHC I presen-
tation pathway by the ER-resident peptidase ERAP. Recent work
by the group of PeterVan Endert identiﬁed IRAP as an endosome-
speciﬁc peptidase required for such peptide-trimming in cross-
presentation (Saveanu et al., 2009). IRAP, which is speciﬁcally
targeted toward endosomes by its amino-terminal cytoplasmic
tail (Hou et al., 2006), displays a broader pH optimum compared
to ERAP, allowing IRAP activity at a slightly acidic endosomal
pH (Georgiadou et al., 2010). IRAP activity might ensure that
antigen-derived peptides, which were generated by proteasomal
degradation in the cytoplasm and re-imported into the endosomes
by endosomal TAP, are trimmed to their optimal size for loading
on MHC I molecules, providing potent cross-presentation by the
phagosome-to-cytosol pathway.
CROSS-PRESENTATION VIA GAP JUNCTIONS-MEDIATED PEPTIDE
TRANSFER
In addition to the vacuolar and the phagosome-to-cytosol cross-
presentation pathway, it has been demonstrated that DCs can
obtain peptides from other cells by gap junctions-mediated cell–
cell contact (Neijssen et al., 2005; Mendoza-Naranjo et al., 2007).
Such peptides are though to directly enter the endogenous MHC
I-restricted presentation pathway via TAP-mediated transport
into the ER. Saccheri et al. (2010) demonstrated that infec-
tion of melanoma cells with salmonella induced an upregula-
tion of Cx43, which increased the formation of gap junctions
with DCs. These gap junctions enabled peptide transfer from the
melanoma cell toward the DC, which resulted in the induction
of an anti-melanoma immune response (Neijssen et al., 2005;
Mendoza-Naranjo et al., 2007; Saccheri et al., 2010). Whether
cross-presentation via gap junctions-mediated antigen transfer
has a broad physiological relevance, however, remains unclear,
especially because cytoplasmic peptides are rapidly degraded by
cytosolic peptidases and display a half-life of only a few seconds
(Reits et al., 2003).
CROSS-DRESSING OF DCS WITH PEPTIDE–MHC I-COMPLEXES
Independent of cross-presentation of internalized and processed
antigens, DCs can also acquire MHC I molecules that are already
loaded with antigen-derived peptides from a donor cell, a process
that has been termed cross-dressing (Dolan et al., 2006; Smyth
et al., 2008). Within this process, the antigen-presenting cell can
obtain peptide–MHC I-complexes from a large variety of living or
apoptotic donor cells. Presentation of such complexes to antigen-
speciﬁc T cells does not require further processing by the DC.
Transfer of the loaded MHC I molecules has been shown to be
mediated by direct cell contact between the DC and the donor cell
rather than by transfer of secreted vesicles like exosomes (Dolan
et al., 2006; Wakim and Bevan, 2011). Such transfer occurred even
at limited antigen concentrations (Smyth et al., 2008) and allows
a direct antigen transfer from infected cells to DCs also in vivo
(Dolan et al., 2006; Wakim and Bevan, 2011). The relevance of
cross-dressing compared to direct or cross-presentation by DCs in
the control of an infection remains to be analyzed further and will
be the topic of intensive future investigations.
INFLUENCE OF DC MATURATION ON CROSS-PRESENTATION
AND ON THE RECRUITMENT OF MHC LOADING MACHINERY
FROM THE ER TOWARD ENDOSOMES
In the absence of inﬂammatory stimuli, cross-presentation of
internalized antigens, which occurs at moderate efﬁciency in
immature DCs (Burgdorf et al., 2008), leads to T cell tolerance.
Once the DC becomes activated by the recognition of microbial
substances, its cross-presentation capacities are enhanced. First, in
maturing DCs, total antigen uptake is increased (Gil-Torregrosa
et al., 2004). Additionally, the composition of the ubiquitin–
proteasome system is altered during DC maturation (Ebstein et al.,
2009) and overall proteasomal activity is increased (Gil-Torregrosa
et al., 2004). Finally, also antigen translocation into the cytoplasm
is increased in maturing DCs (Gil-Torregrosa et al., 2004). Since
such antigen translocation is mediated by proteins derived from
the ER, the transport of these proteins toward the endosomes is
an important prerequisite for cross-presentation.
A process termed ER-mediated phagocytosis has been postu-
lated to mediate the transport of ER membrane components to
endosomal compartments (Gagnon et al., 2002). In this process,
the ER serves as amembrane donor for the developing phagosome,
which then contains fragments of both the ER and the plasma
membrane. This model, however, has been discussed controver-
sially (Touret et al., 2005) and its physiological signiﬁcance remains
unclear. The same is true for transient fusions between the ER and
endosomes after internalization, which has also been proposed to
be a putative mechanism for delivery of ER components to endo-
somal membranes. The existence of such fusion events, however,
has never been clearly demonstrated.
Increasing evidence points out that the transport of ER com-
ponents to endosomes is a process that is controlled very tightly
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and that is increased during DC maturation. Goldszmid et al.
(2009) demonstrated that the transport of ER components to
Toxoplasma gondii-containing phagosomes only occurred if living
protozoa were present in the phagosome. Additionally, our group
demonstrated that TAP is only transported toward the endosomal
membrane upon DC stimulation with LPS and due to the acti-
vation of the TLR4–MyD88 signaling pathway (Burgdorf et al.,
2008). Likewise, the group of Peter Van Endert demonstrated that
in unstimulated DCs, TAP is not present in IRAP-containing early
endosomes (Saveanu et al., 2009). After phagocytosis of yeast cells,
however, a clear TAP translocation from the ER toward the IRAP-
containing endosomes was observed. Importantly, ERAP was not
recruited to the antigen-containing endosomes, but maintained in
the ER. This demonstrates that not all ER components are trans-
ported toward the endosome, but a process regulated by microbial
substances rather induces the transport of only selected ER pro-
teins toward the endosomal membrane. The selectivity of this
transport also implicates that these ER components might not be
recruitedbyER-mediated endocytosis or by transient fusion events
between the ER and the endosomes, since such events would result
in an equal transport of all ER components toward the antigen-
containing endosomes. These resultsmight rather imply that upon
stimulation with microbial substances, selective members of the
ER undergo a directed ER-to-endosome transport.
SuchTLR ligand-mediated transport from theER toward endo-
somes reminds very much of the transport of several TLRs them-
selves. It has been demonstrated that TLR3, TLR7, and TLR9 in
unstimulated DCs are localized in the ER (Latz et al., 2004). Upon
DC stimulation with TLR ligands, however, these receptors are
rapidly translocated toward early endosomes, from where their
signaling takes place (Kagan et al., 2008). It is thinkable that, upon
DC stimulation with endotoxin, some ER components involved in
antigen presentation are translocated along with the TLRs toward
early endosomes, where they can exert their function in cross-
presentation. This transport has been shown to occur without
passing the golgi and is regulated by the polytopic membrane
protein UNC93B1 (Kim et al., 2008). Interestingly, a loss of func-
tion mutation of UNC93B1 has a severe inﬂuence on antigen
presentation and in particular cross-presentation (Tabeta et al.,
2006). Whether this loss of cross-presentation capacity indeed is
due to an impaired transport of the cross-presentation machinery
toward endosomes upon TLR signaling, however, still needs to be
investigated.
Additional to the recruitment of ER components by TLR lig-
ands, the endocytic receptor seems to play an important role
for the recruitment of soluble ERAD components. In a recent
study, we demonstrated that the MR, which targets its antigens
speciﬁcally toward cross-presentation as described above, plays an
important role in the recruitment of p97 (Zehner et al., 2011).
During the ERAD process, p97 is recruited toward the ER by bind-
ing to poly-ubiquitinated proteins at the ER membrane (Ye et al.,
2003). The recruitment of p97 toward the endosomal membrane
for cross-presentation seems to be regulated in a very similar way.
P97 recruitment for cross-presentation of MR-internalized anti-
gens was regulated by ubiquitination of the MR (Zehner et al.,
2011). Ligand binding to the MR induced poly-ubiquitination
of its cytoplasmic tail. Without receptor poly-ubiquitination, no
p97 recruitment toward the endosomal membrane took place and
antigen transport into the cytoplasm and cross-presentation were
impaired. These data demonstrate that the endocytic receptor is
not only required for antigen targeting into a suited endosomal
compartment for cross-presentation as described above, but also is
of decisive importance for the antigen to get out of the endosomal
compartment to reach the cytosol for proteasomal degradation.
CONCLUSION
In conclusion, it is important to emphasize that there aremany dif-
ferent roads to cross-presentation. Whether extracellular antigens
are cross-presented via the cytosolic or via the phagosome-to-
cytosol pathway might be determined by the physiological condi-
tions of both the antigen-presenting cell and the antigen itself or
might even vary for different epitopes of the same antigen.
Furthermore, future experiments are needed to fully under-
stand the molecular mechanisms underlying cross-presentation.
Of special interest will be the identiﬁcation of the pore complex
that mediated antigen translocation into the cytoplasm, which
without any doubt is one of the most important remaining open
questions regarding cross-presentation. In this context, it will be
important to unequivocally determine the role of Sec61 and the
other postulated candidates in building the transmembrane pore
complex.
Another question that will be subject of intense research is
the transport of members of the MHC I loading machinery from
theER toward antigen-containing endosomes. Future experiments
will show whether such components might be transported along
with the different TLRs as postulated in this review, providing an
explanation for the dependency of efﬁcient cross-presentation on
DC activation by TLR ligands.
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